Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound that is approved the United States Food and Drug Administration (FDA) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. During the American Society of Hematology (ASH) Annual Meeting, new results of this myeloma drug were presented. Dr Cristina Gasparetto, Duke Cancer Institute, North Corolina, USA, explains for Myeloma Patients Europe (MPE) the main results of selinexor.
Leave a Reply